Mass screening for neuroblastoma at 6 months of age : Difficult to justify.
Annual Meeting of the Pacific Association of Pediatrics Surgeons. Maui, HI, USA, 1998/06/09.
A statistical analysis of the mass screening for neuroblastoma in Japan based on a population study rarely has been reported.
This study aims to evaluate retrospectively the effectiveness of mass screening at 6 months of age using the available population data.
The data on the neuroblastoma cases registered by the Committee for Pediatric Solid Malignant Tumors in the Kyushu area were analyzed based on both screened and unscreened populations in the Kyushu area.
From 1988 to 1992, the cumulative incidence of neuroblastoma in children less than 5 years of age was 82 in 484,599 for screened children, and 11 in 92,966 for unscreened children, respectively.
Fourteen of the 82 screened patients had negative findings at 6 months of age (MS-negative cases).
No significant difference was observed in the cumulative mortality rates from neuroblastoma in children younger than 5 years of age between the screened children and the unscreened children.
Six of seven patients who died among the screened children were MS-negative cases with stage III or IV disease.
In addition, no significant difference was found in the cumulative mortality rates from the neuroblastoma cases in patients less than 5 years of age between the children screened from 1988 to 1992 (7 of 484,599) and all children from 1980 to 1984 (14 of 668,084). (...)
Mots-clés Pascal : Neuroblastome, Dépistage, Programme sanitaire, Japon, Asie, Evaluation, Efficacité, Nourrisson, Homme, Système nerveux pathologie, Système nerveux sympathique pathologie, Tumeur maligne
Mots-clés Pascal anglais : Neuroblastoma, Medical screening, Sanitary program, Japan, Asia, Evaluation, Efficiency, Infant, Human, Nervous system diseases, Autonomic neuropathy, Malignant tumor
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0120141
Code Inist : 002B17E. Création : 16/11/1999.